Compare WIA & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WIA | NYXH |
|---|---|---|
| Founded | 2003 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 188.0M | 161.9M |
| IPO Year | N/A | 2021 |
| Metric | WIA | NYXH |
|---|---|---|
| Price | $8.06 | $1.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | 32.2K | ★ 244.0K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 12.29% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $213.98 |
| Revenue Next Year | N/A | $126.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.95 | $1.26 |
| 52 Week High | $8.54 | $8.59 |
| Indicator | WIA | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 43.48 | 38.35 |
| Support Level | $7.95 | $1.26 |
| Resistance Level | $8.31 | $1.70 |
| Average True Range (ATR) | 0.05 | 0.11 |
| MACD | -0.00 | 0.05 |
| Stochastic Oscillator | 35.71 | 37.88 |
Western Asset Inflation Linked Income Fund is a diversified, closed-end management investment company. The primary investment objective of the group is to provide current income while its secondary investment objective is capital appreciation. Under normal market conditions and at the time of purchase, the Fund will invest at least 80% of its total managed assets in inflation-linked securities and at least 60% of its total managed assets in U.S. Treasury Inflation Protected Securities (TIPS). The Fund may also invest up to 40% of its total managed assets in non-U.S. dollar investments.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.